Premium
Improving funding for OUD medications will go only so far, study suggests
Author(s) -
Enos Gary
Publication year - 2019
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32396
Subject(s) - reimbursement , addiction , agonist , buprenorphine , business , opioid , medicine , actuarial science , family medicine , psychiatry , political science , health care , law , receptor
Funding clearly plays a pivotal role in encouraging addiction treatment providers to adopt agonist therapy–based strategies to combat opioid dependence, but a new study suggests that reimbursement alone won't maximize use of evidence‐based medication treatments.